UB Paderborn / Katalog / Suche / in CDI

1 – 12 von 12

Sortiert nach

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Osteoporosis international, 2013-01, Vol.24 (1), p.301-310

2013

Link zum Volltext

Verfügbarkeit prüfen

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

Calcified tissue international, 2002-08, Vol.71 (2), p.103-111

2002

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

Osteoporosis international, 2012-01, Vol.23 (1), p.267-276

2012

Link zum Volltext

Verfügbarkeit prüfen

Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age

The New England journal of medicine, 1998-02, Vol.338 (8), p.485-492

1998

Link zum Volltext

Verfügbarkeit prüfen

Ultrasound protocols to measure carotid intima-media thickness: a post-hoc analysis of the OPAL study

Current medical research and opinion, 2009-01, Vol.25 (1), p.109-122

2009

Link zum Volltext

Verfügbarkeit prüfen

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

Annals of internal medicine, 1999-12, Vol.131 (12), p.935

1999

Link zum Volltext

Verfügbarkeit prüfen

Clinical Investigations: The Ecacy and Tolerability of Risedronate Once a Week for the Treatment of Postmenopausal Osteoporosis

Calcified tissue international, 2002-08, Vol.71 (2), p.103

2002

Link zum Volltext

Verfügbarkeit prüfen

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data

Calcified tissue international, 2013-01, Vol.92 (1), p.59-67

2013

Link zum Volltext

Verfügbarkeit prüfen

The Efficacy and Tolerability of a Monthly Dosing Regimen of 75mg Risedronate Dosed on 2 Consecutive Days a Month for the Treatment of Postmenopausal Women with Osteoporosis – 2 Year Study Results

Journal of clinical densitometry, 2009, Vol.12 (3), p.393-394

2009

Link zum Volltext

Verfügbarkeit prüfen

Prevention of Bone Loss With Alendronate in Postmenopausal Women Under 60 Years of Age

Obstetrical & gynecological survey, 1998-06, Vol.53 (6), p.367-368

1998

Link zum Volltext

Verfügbarkeit prüfen

Information Communication System

Journal of chemical documentation, 1971-08, Vol.11 (3), p.174-178

1971

Link zum Volltext

Verfügbarkeit prüfen

Studies on cell division. II. X-radiation as a division inhibiting agent

Journal of bacteriology, 1954-04, Vol.67 (4), p.394-401

1954

Link zum Volltext

Verfügbarkeit prüfen

1 – 12 von 12

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(11)
Mit Volltextzugriff
(11)

Publikationsform

Artikel
(12)

Sprache

Englisch
(12)
Japanisch
(2)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age

Ultrasound protocols to measure carotid intima-media thickness: a post-hoc analysis of the OPAL study

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

Clinical Investigations: The Ecacy and Tolerability of Risedronate Once a Week for the Treatment of Postmenopausal Osteoporosis

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data

The Efficacy and Tolerability of a Monthly Dosing Regimen of 75mg Risedronate Dosed on 2 Consecutive Days a Month for the Treatment of Postmenopausal Women with Osteoporosis – 2 Year Study Results

Prevention of Bone Loss With Alendronate in Postmenopausal Women Under 60 Years of Age

Information Communication System

Studies on cell division. II. X-radiation as a division inhibiting agent

Suchergebnisse filtern